Listen to this page using ReadSpeaker
Posts tagged arvo

ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research

future of retinal researchThe National Eye Institute’s (NEI) establishment of its Audacious Goals in 2013 was a watershed moment in the drive to cure blinding retinal diseases. The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases. Most important, it means that the NEI is making significant investments in research that will benefit people with retinal conditions, such as retinitis pigmentosa, Usher syndrome, Stargardt disease, and age-related macular degeneration.
Continue Reading…

ARVO 2015 Highlight: AMD Gene Therapy Performs Encouragingly in Human Study

an AMD eyeWhile treatments such as Lucentis®, Avastin®, and Eylea® have been saving and restoring vision for people with wet age-related macular degeneration (AMD) over the last several years, they have a significant drawback: The therapies require regular injections into the eye—in some cases, monthly—for the life of the patient.
Continue Reading…

ARVO 2015 Highlight: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes

gene editingI just returned from the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), the world’s largest eye-research conference, held this year in Denver. It attracted more than 11,000 scientists and physicians, including many of the 187 retinal researchers funded by the Foundation. The FFB science team and I worked feverishly to learn as much as possible about the latest news from the retinal-research front. It was truly exhilarating—albeit, at times, overwhelming.
Continue Reading…

ARVO 2014: LCA Gene Therapy Recipient Featured During Keynote

Yannick Duwe and his father, Tony, at ARVOGene-therapy pioneer Jean Bennett, M.D., Ph.D., may have been the keynote speaker for the closing session at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), but Yannick Duwe, a 15-year-old patient with Leber congenital amaurosis (LCA) who was treated in her clinical trial six years ago, stole the show. He and his father, Tony, were part of a panel which also included members of Dr. Bennett’s research team.
Continue Reading…

ARVO 2014: European Collaboration Developing Cross-Cutting, Vision-Saving Therapies

The DRUGSFORD collaborativeOne of the most intriguing reports on therapy development at the annual meeting of the Association for Research in Vision and Ophthalmology came from a European collaborative project called DRUGSFORD, which is derived from the phrase “drugs for retinal degeneration.” With funding from the European Union, the project brings together three research groups and two companies to develop a therapy that can treat a disease pathway common to many retinal degenerations. Simply put, they’re creating therapies that can save vision in as many people as possible, independent of the genetic cause of disease.
Continue Reading…

ARVO 2014: Three Promising CEP290 Gene Therapy Alternatives

Renee Ryalls explains the dual-AAV gene therapy she's developing.While gene therapies for retinal degenerative diseases are making groundbreaking strides in both human and laboratory studies, the most widely and successfully used human-engineered virus for delivering replacement genes to retinal cells — the adeno-associated virus, or AAV — has one significant limitation. It can’t deliver relatively large genes, namely those larger than about 4.5 or 5 kilobases (kb). (Bases are the building blocks of a gene, and its size is expressed in kilobases.)
Continue Reading…

ARVO 2014: The Latest Retinal Research News from the Magic Kingdom

The Foundation’s science team is in Orlando over the next week for the annual meeting of the Association for Research in Vision in Ophthalmology, which convenes more than 10,000 of the world’s top eye researchers to report on their latest achievements.
Continue Reading…

Grow Your Own: Harnessing Muller Glia for Retinal Regeneration

As I wind down the week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), I’d like to introduce an intriguing therapeutic approach to retinal degeneration that would be a home run if perfected. It’s called retinal regeneration, and it happens to be right in line with the National Eye Institute’s life-changing audacious goal, announced on Monday: “to regenerate the neurons and neural connections in the eye and visual system.”
Continue Reading…

ARVO Update on Optogenetics: New Light for People with Advanced Vision Loss

Keirnan Willett.One of the promising emerging approaches to restoring vision in people with advanced retinal diseases is a form of therapy known as optogenetics. In essence, this type of treatment restores light sensitivity — and, potentially, meaningful vision — to people who have very little, if any, vision remaining. An important benefit of optogenetics is that it should work regardless of the underlying genetic defect causing the disease. While it is too early to speculate how well optogenetics will ultimately work, we’re hoping it ends up retiring a lot of white canes. Continue Reading…

RP Gene Therapy Clinical Trial Update from ARVO

Drs. Nicola Ghazi (left) and Doug Vollrath. I am always pleased to hear reports on human studies for retinal diseases. And such is the case with a research poster I just reviewed at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. It described a new clinical trial underway for a potentially life-changing gene therapy for people with autosomal recessive retinitis pigmentosa (MERTK mutations) taking place at King Khaled Eye Specialist Hospital in Saudi Arabia.
Continue Reading…